Allergic Rhinitis Due to Grass Pollen Clinical Trial
Official title:
Determination of Grass Pollen Allergen Concentration Inducing Rhinoconjunctivitis Symptoms in Subjects Allergic to Grass Pollen in ALYATEC Allergen Exposure Chamber
The aim of this study is to determine the optimal concentration of grass pollen allergens inducing rhinoconjunctivitis in subjects allergic to grass pollen in ALYATEC allergen exposure chamber. Four concentrations of grass pollen allergen (Phl p 5) are tested during 3-hour exposures: 0, 30, 60 and 90 ng/m3.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03290248 -
Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis
|
Phase 1/Phase 2 | |
Completed |
NCT04878237 -
Kinetics of Nasal Cytokine Responses to Mechanical Stimulation
|
N/A | |
Completed |
NCT04802616 -
The Influence of Nonspecific Immunostimulation on Changes in the Concentration of iNKT Cells
|
Phase 3 | |
Active, not recruiting |
NCT05297760 -
Intralymphatic Immunotherapy With Polvac Grass & Rye Allergen Extract
|
Phase 1/Phase 2 | |
Recruiting |
NCT06061848 -
Intralymphatic Immunotherapy Enhanced by Vitamin-D, a Randomized Placebo-controlled Trial and Comparison With SLIT
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04700852 -
Efficacy of Puressentiel Protective Nasal Spray in Allergic Rhinitis
|
N/A | |
Completed |
NCT05037955 -
ILIT: Follow-up of Rhinitis Quality of Life
|
||
Active, not recruiting |
NCT05191186 -
Documentation of Efficacy of Intralymphatic Allergen Immunotherapy
|
Phase 3 | |
Completed |
NCT04210193 -
Is Intralymphatic Allergen Immunotherapy Effective and Safe?
|
Phase 2/Phase 3 | |
Completed |
NCT01953471 -
Prospective Observational Study for Determination of Minimal Clinically Important Difference of Allergic Rhinitis Symptoms Due to Grass Pollen (Equinoxe 2)
|
N/A |